Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope

Journal of Virology

Volumn 79, Issue 19, 2005, Pages 12394-12400

  Raviv, Yossef ^a,b   Viard, Mathias ^a   Bess Jr , Julian W ^b   Chertova, Elena ^b   Blumenthal, Robert ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 IODONAPHTHYLAZIDE; ALKYLATING AGENT; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 4E10; MONOCLONAL ANTIBODY B12; NUCLEOCAPSID PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIGEN STRUCTURE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; PRIORITY JOURNAL; PROTEIN MODIFICATION; RETROVIRUS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SIMIAN IMMUNODEFICIENCY VIRUS; TARGET CELL; VIRUS ENVELOPE; VIRUS INACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; AZIDES; CELL FUSION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HIV; HYDROPHOBICITY; NUCLEOCAPSID PROTEINS; RETROVIRIDAE; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL ENVELOPE PROTEINS; VIRUS INACTIVATION;

HIV TYPE 1; HUMAN IMMUNODEFICIENCY VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 25144500093     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.19.12394-12400.2005     Document Type: Article

References (32)

1. Arthur, O. L., J. W. Bess, Jr., E. N. Chertova, J. L. Rossio, M. T. Esser, R. E. Benveniste, L. E. Henderson, and J. D. Lifson. 1998. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. AIDS Res. Hum. Retrovir. 14:S311-S319.
2. Baba, W. T., V. Liska, R. H. Lehman, J. Vlasak, W. Xu, S. Ayehunie, L. C. Cavacini, M. R. Posner, H. Kattinger, G. Stiegler, B. R. Bernacky, T. A. Rizvi, R. Schmidt, L. R. Hill, M. E. Keeling, Y. Lu, j. E. Wright, T. C. Chou, and R. M. Ruprecht. 2000. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:200-206.
3. Benade, E. L., Y. Shumaker, X. X. Chen, and Y. R. Dodd. 1994. Inactivation of free and cell-associated human immunodeficiency virus in platelet suspensions by aminomethyltrimethylpsoralen and ultraviolet light. Transfusion 34:680-684.
4. 125I]iodonaphthyl azide, a reagent to determine the penetration of proteins into the lipid bilayer of biological membranes. Biochemistry 17:1484-1489.
5. Blanco, J., J. Barretina, B. Clotet, and A. J. Este. 2004. R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism. J. Leukoc. Biol. 76:804-881.
6. Burton, R. D., J. Pyati, R. Koduri, S. J. Sharp, G. B. Thornton, P. W. H. I. Parren, L. S. W. Sawter, R. M. Hendry, N. Dunlop, P. L. Nara, M. Lamancchia, E. Garatty, E. R. Stiehm, Y. J. Bryson, Y. Cao, J. P. Moore, D. D. Ho, and C. F. Barbas III. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
7. Calarota, A. S., and B. D. Weiner. 2003. Present status of human vaccine development. AIDS 17:S73-S84.
8. Chertova, E., J. W. Bess, Jr., J. B. Crise, R. C. Sowder II, M. T. Schaden, J. M. Hilburn, J. A. Hoxie, R. E. Benveniste, J. D. Lifson, L. E. Henderson, and L. O. Arthur. 2002. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 76:5315-5325.
9. Conley, J. A., J. A. Kessler II, L. J. Boots, P. M. McKenna, W. A. Schleif, E. A. Emini, G. E. Mark III, H. Katinger, E. K. Kobb, S. T. Lunceford, S. R. Rouse, and K. K. Murthy. 1996. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J. Virol. 70:6751-6758.
10. Dimitrov, S. D., and R. Blumenthal. 1994. Photoinactivation and kinetics of membrane fusion mediated by the human immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 68:1956-1961.
11. D'Souza, M. P., D. Livnat, J. A. Bradac, and S. H. Bridges. 1997. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. J. Infect. Dis. 175:1056-1062.
12. Henderson, E. E., G. Tudor, and J. Yang. 1992. Inactivation of the human immunodeficiency virus type 1 (HIV-1) by ultraviolet and X irradiation. Radiat. Res. 131:169-176.
13. LaBonte, A. J., N. Madani, and J. Sodroski. 2003. Cytolysis by CCR5-using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression. J. Virol. 70:6645-6659.
14. Lifson, D. J., J. L. Rossio, M. Piatak, Jr., J. Bess, Jr., E. Chertova, D. K. Schneider, V. J. Coalter, B. Poore, R. F. Riser, R. J. Imming, A. J. Scarzello, L. E. Henderson, W. G. Alvord, V. M. Hirsch, R. E. Benveniste, and L. O. Arthur. 2004. Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. AIDS Res. Hum. Retrovir. 20:772-787.
15. Mariner, J. M., J. B. McMahon, B. R. O'Keefer, K. Nagashima, and M. R. Boyd. 1998. The HIV-inactivating protein, cyanovirin-N, does not block gp120-mediated virus-to-cell binding. Biochem. Biophys. Res. Commun. 248:841-845.
16. Mascola, R. J., G. Stiegler, T. C. VanCott, H. Kattinger, C. B. Carpenter, C. E. Hanson, H. Beary, D. Hayes, S. S. Frankel, D. L. Birx, and M. G. Lewis. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210.
17. Mascola, R. J., M. G. Lewis, G. Stiegler, D. Harris, T. C. VanCott, D. Hayes, M. K. Lauder, C. R. Brown, C. V. Sapan, S. S. Frankel, Y. Lu, M. L. Robb, H. Kattinger, and D. L. Birx. 1999. Protection of macaques against pathogenic simian/human immudodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:4009-4018.
18. Murphey-Corb, M., L. N. Martin, M. Miller, M. West, S. Ohkawa, G. B. Baskin, J. Y. Zhang, S. D. Putney, A. C. Allison, D. A. Eppstein. 1989. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science 246:1293-1297.
19. Nyambi, N. P., S. Burda, L. Bastiani, and C. Williams. 2001. A virus binding assay for studying the antigenic landscape on intact, native, primary human immunodeficiency virus-type 1. J. Immunol. Methods 253:253-262.
20. Race, E., C. A. Stein, M. D. Wigg, A. Baksh, M. Addawe, P. Frezza, and J. S. Oxford. 1995. A multistep procedure for the chemical inactivation of human immunodeficiency virus for use as an experimental vaccine. Vaccine 13:1567-1575.
21. Raviv, Y., T. Bercovici, C. Gitler, and Y. Salomon. 1984. Selective photoinduced uncoupling of the response of adenylate cyclase to gonadotropins by 5-iodonaphtyl 1-azide. Biochemistry 23:503-508.
22. Raviv, Y., M. Viard, J. W. Bess, Jr., and R. Blumenthal. 2002. Quantitative measurement of fusion of HIV-1 and SIV with cultured cells using photosensitized labeling. Virology 293:243-251.
23. Reed, L. J., and H. Muench. 1938. A simple method of estimating 50 percent endpoints. Am. J. Hyg. 27:493-497.
24. Rein, A., D. E. Ott, J. Mirro, L. O. Arthur, W. Rice, and L. E. Henderson. 1996. Inactivation of murine leukemia virus by compounds that react with the zinc finger in the viral nucleocapsid protein. J. Virol. 70:4966-4972.
25. Rice, G. W., J. G. Supko, L. Malspeis, R. W. Buckheit, Jr., D. Clanton, M. Bu, L. Greham, C. A. Schaeffer, J. A. Turpin, J. Domagala, R. Gogliotti, J. P. Bader, S. M. Halliday, L. Cohen, R. C. Sowder II, L. O. Arthur, and L. E. Henderson. 1995. Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science 270:1194-1197.
26. Roos, W. J., F. M. Maughan, Z. Liao, K. E. J. Hildreth, and E. J. Clements. 2000. LuSIV cells: a reporter cell line for the detection and quantitation of a single cycle of HIV and SIV replication. Virology 273:307-315.
27. Rossio, L. J., M. T. Esser, K. Suryanarayana, D. K. Schneider, J. W. Bess, Jr., G. M. Vasquez, T. A. Willtrout, E. Chertova, M. K. Grimes, Q. Sattentau, L. O. Arthur, L. E. Henederson, and J. D. Lifson. 1998. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J. Virol. 72:7992-8001.
28. Sattentau, O. J. 1995. Conservation of HIV-1 gp120 neutralizing epitopes after formalin inactivation. AIDS 9:1383-1385.
29. Spearman, P. 2003. HIV vaccine development: Lessons from the past and promise for the future. Curr. HIV Res. 1:101-120.
30. Stiegler, G., R. Kunert, M. Purtscher, S. Wolbank, R. Voglauer, F. Steidl, and H. Katinger. 2001. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on GP41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retrovir. 17:1757-1765.
31. Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J. P. Moore, and H. Katinger. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-1108.
32. Wei, X., J. M. Decker, H. Liu, Z. Zhang, R. B. Arani, J. M. Kilhy, M. S. Saag, X. Wu, G. M. Shaw, J. C. Kappes. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.